# OnCo record neuroblastoma-intermediate-risk (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/neuroblastoma-intermediate-risk/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "neuroblastoma-intermediate-risk" ;
  schema:name "Intermediate-risk neuroblastoma"@en ;
  schema:alternateName "INRG intermediate-risk neuroblastoma"@en, "Unresectable localised neuroblastoma"@en, "Stage M neuroblastoma in infants"@en ;
  schema:description "Intermediate-risk neuroblastoma sits between the tumours that go away on their own and the high-risk disease that needs everything. A few cycles of moderate chemotherapy followed by surgery cure most children, and trials have spent twenty years showing how few cycles are enough."@en ;
  schema:url <https://onco.cc/cancers/neuroblastoma-intermediate-risk/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neuroblastoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Neuroblastoma>, <https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq> ;
  onco:tag "subtype-page", "paediatric" ;
  onco:related <https://onco.cc/cancers/neuroblastoma-low-risk/>, <https://onco.cc/cancers/neuroblastoma-high-risk/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/mibg-theranostics/> ;
  onco:institutions <https://onco.cc/institutions/childrens-oncology-group/>, <https://onco.cc/institutions/siop-europe/> ;
  onco:terms <https://onco.cc/terms/inrg-staging/>, <https://onco.cc/terms/mycn-amplification/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/segmental-chromosomal-aberrations/>, <https://onco.cc/terms/urinary-catecholamines/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-inrg-cohn-jco-2009/>, <https://onco.cc/key-papers/paper-a3961-intermediate-risk-neuroblastoma-baker-nejm-2010/>, <https://onco.cc/key-papers/paper-anbl0531-twist-jco-2019/> ;
  onco:pipeline <https://onco.cc/terms/inrg-staging/>, <https://onco.cc/ideas/idea-mfbg-pet-replaces-mibg/>, <https://onco.cc/technologies/mibg-theranostics/>, <https://onco.cc/technologies/cardio-oncology/> ;
  onco:standardOfCare <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/terms/inrg-staging/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/mibg-theranostics/>, <https://onco.cc/terms/inrg-staging/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/radiotherapy/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/fertility-preservation/> .